Oxymetazoline - RDD Pharma

Drug Profile

Oxymetazoline - RDD Pharma

Alternative Names: RDD 0315

Latest Information Update: 04 Aug 2016

Price : $50

At a glance

  • Originator RDD Pharma
  • Class Decongestants; Imidazoles; Skin disorder therapies; Small molecules
  • Mechanism of Action Alpha adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Faecal incontinence

Most Recent Events

  • 21 May 2016 Updated efficacy and safety data from a phase I/II trial in Faecal Incontinence presented at Digestive Disease Week 2016 (DDW 2016)
  • 07 Jan 2016 Efficacy and adverse events data from a phase-II trial in Faecal incontinence released by RDD Pharma
  • 21 Oct 2015 RDD Pharma plans a phase IIb trial for Faecal incontinence
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top